tetano
Editor, Senior Moderator
Am J Transl Res
. 2022 Aug 15;14(8):5719-5729.
eCollection 2022.
Higher benefit-risk ratio of COVID-19 vaccination in patients with schizophrenia and major depressive disorder versus patients with bipolar disorder when compared to controls
Jingjing Zhu[SUP] 1 [/SUP], Hongjun Tian[SUP] 2 [/SUP], Haibo Wang[SUP] 3 [/SUP], Haiping Yu[SUP] 4 [/SUP], Chuanxin Liu[SUP] 5 [/SUP], Lina Wang[SUP] 2 [/SUP], Qianchen Li[SUP] 3 [/SUP], Tao Fang[SUP] 4 [/SUP], Feng Jia[SUP] 3 [/SUP], Yachen Li[SUP] 3 [/SUP], Ranli Li[SUP] 3 [/SUP], Xiaoyan Ma[SUP] 3 [/SUP], Yun Sun[SUP] 3 [/SUP], Jing Ping[SUP] 3 [/SUP], Ziyao Cai[SUP] 1 [/SUP], Deguo Jiang[SUP] 1 [/SUP], Langlang Cheng[SUP] 1 [/SUP], Min Chen[SUP] 5 [/SUP], Sha Liu[SUP] 6 [/SUP], Yong Xu[SUP] 6 [/SUP], Qingying Xu[SUP] 7 [/SUP], Guangdong Chen[SUP] 1 [/SUP], Wei Liu[SUP] 8 [/SUP], Waihui Yue[SUP] 9 [/SUP], Xueqin Song[SUP] 10 [/SUP], Chuanjun Zhuo[SUP] 1 2 4 10 [/SUP]
Affiliations
Abstract
Patients with major psychiatric disorders (MPD) that include schizophrenia (SCH), bipolar disorder (BP), and major depressive disorder (MDD) are at increased risk for coronavirus disease 2019 (COVID-19). However, the safety and efficacy of COVID-19 vaccines in MPD patients have not been fully evaluated. This study aimed to investigate adverse events (AEs)/side effects and efficacy of COVID-19 vaccines in MPD patients. This retrospective study included 2034 patients with SCH, BP, or MDD who voluntarily received either BBIBP-CorV or Sinovac COVID-19 vaccines, and 2034 matched healthy controls. The incidence of AEs/side effects and the efficacy of COIVD-19 vaccinations among the two groups were compared. The risk ratio (RR) of side effects in patients with MPD was 0.60 (95% confidence interval [CI]: 0.53-0.68) after the first dose and 0.80 (95% CI: 0.65-0.99) following the second dose, suggesting a significantly lower risk in the MPD group versus healthy controls. The RRs of AEs did not differ between patients and controls. Notably, fully vaccinated patients exhibited a decreased risk of influenza with or without fever compared with controls (RR=0.38, 95% CI: 0.31-0.46; RR=0.23, 95% CI: 0.17-0.30; respectively). Further subgroup comparisons revealed a significantly lower risk of influenza with fever in MDD (RR=0.13, 95% CI: 0.08-0.21) and SCH (RR=0.24, 95% CI: 0.17-0.34) than BP (RR=0.85, 95% CI: 0.69-1.06) compared to controls. We conclude that the benefit-risk ratio of COVID-19 vaccination was more favorable in SCH or MDD versus BP when compared with controls. These data indicate that COVID-19 vaccines are safe and protective in patients with MPD from COVID-19.
Keywords: COVID-19 vaccine; SARS-CoV-2; bipolar disorder; effectiveness; major depressive disorder; safety; schizophrenia.
. 2022 Aug 15;14(8):5719-5729.
eCollection 2022.
Higher benefit-risk ratio of COVID-19 vaccination in patients with schizophrenia and major depressive disorder versus patients with bipolar disorder when compared to controls
Jingjing Zhu[SUP] 1 [/SUP], Hongjun Tian[SUP] 2 [/SUP], Haibo Wang[SUP] 3 [/SUP], Haiping Yu[SUP] 4 [/SUP], Chuanxin Liu[SUP] 5 [/SUP], Lina Wang[SUP] 2 [/SUP], Qianchen Li[SUP] 3 [/SUP], Tao Fang[SUP] 4 [/SUP], Feng Jia[SUP] 3 [/SUP], Yachen Li[SUP] 3 [/SUP], Ranli Li[SUP] 3 [/SUP], Xiaoyan Ma[SUP] 3 [/SUP], Yun Sun[SUP] 3 [/SUP], Jing Ping[SUP] 3 [/SUP], Ziyao Cai[SUP] 1 [/SUP], Deguo Jiang[SUP] 1 [/SUP], Langlang Cheng[SUP] 1 [/SUP], Min Chen[SUP] 5 [/SUP], Sha Liu[SUP] 6 [/SUP], Yong Xu[SUP] 6 [/SUP], Qingying Xu[SUP] 7 [/SUP], Guangdong Chen[SUP] 1 [/SUP], Wei Liu[SUP] 8 [/SUP], Waihui Yue[SUP] 9 [/SUP], Xueqin Song[SUP] 10 [/SUP], Chuanjun Zhuo[SUP] 1 2 4 10 [/SUP]
Affiliations
- PMID: 36105010
- PMCID: PMC9452368
Abstract
Patients with major psychiatric disorders (MPD) that include schizophrenia (SCH), bipolar disorder (BP), and major depressive disorder (MDD) are at increased risk for coronavirus disease 2019 (COVID-19). However, the safety and efficacy of COVID-19 vaccines in MPD patients have not been fully evaluated. This study aimed to investigate adverse events (AEs)/side effects and efficacy of COVID-19 vaccines in MPD patients. This retrospective study included 2034 patients with SCH, BP, or MDD who voluntarily received either BBIBP-CorV or Sinovac COVID-19 vaccines, and 2034 matched healthy controls. The incidence of AEs/side effects and the efficacy of COIVD-19 vaccinations among the two groups were compared. The risk ratio (RR) of side effects in patients with MPD was 0.60 (95% confidence interval [CI]: 0.53-0.68) after the first dose and 0.80 (95% CI: 0.65-0.99) following the second dose, suggesting a significantly lower risk in the MPD group versus healthy controls. The RRs of AEs did not differ between patients and controls. Notably, fully vaccinated patients exhibited a decreased risk of influenza with or without fever compared with controls (RR=0.38, 95% CI: 0.31-0.46; RR=0.23, 95% CI: 0.17-0.30; respectively). Further subgroup comparisons revealed a significantly lower risk of influenza with fever in MDD (RR=0.13, 95% CI: 0.08-0.21) and SCH (RR=0.24, 95% CI: 0.17-0.34) than BP (RR=0.85, 95% CI: 0.69-1.06) compared to controls. We conclude that the benefit-risk ratio of COVID-19 vaccination was more favorable in SCH or MDD versus BP when compared with controls. These data indicate that COVID-19 vaccines are safe and protective in patients with MPD from COVID-19.
Keywords: COVID-19 vaccine; SARS-CoV-2; bipolar disorder; effectiveness; major depressive disorder; safety; schizophrenia.